Pleading guilty to misbranding one of its heart drugs, Johnson & Johnson’s Scios unit has agreed to pay an $85 million fine, according to a Bloomberg report.
Scios was charged in July with misbranding its drug, Natrecor, one of the first drugs for congestive heart failure when approved in 2001, since the drug’s label lacked adequate directions for use. Under a plea agreement, Scios will be placed under organizational probation for three years along with the payment of the fine.
While the government agreed not to prosecute Scios or J&J for other offenses related to the marketing of Natrecor, that exemption doesn’t apply to False Claims Act liability, according to the report.
Related Articles on Pharmaceutical Companies and Fraud:
New Jersey’s Par Pharmaceutical to Pay $154M to Settle Medicaid Fraud Allegations
Mississippi Wins More Than $38M in Suit Against Sandoz
Justice Department Issues Subpoenas to Merck Over Drug Marketing
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.